Zacks Investment Research upgraded shares of ONCONOVA THERAP (ONTX) from NEUTRAL to OUTPERFORM on December 26, 2014, with a target price of $4.10.
Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company's products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on ONCONOVA THERAP (ONTX),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment